Clinical Trials Logo

Multiple Myeloma Stage I clinical trials

View clinical trials related to Multiple Myeloma Stage I.

Filter by:
  • None
  • Page 1

NCT ID: NCT03792620 Recruiting - Clinical trials for Multiple Myeloma Stage I

Daratumumab Intensified Treatment to Eligible MM New Patients CTD-Dara Induction, Follow by Dara Consolidation

MAXDARA
Start date: November 20, 2018
Phase: Phase 3
Study type: Interventional

The best induction protocol to eligible multiple myeloma patients was not established. Combination of three drugs demonstrated better outcomes than two drugs combo. Nevertheless, until now four drugs combo did not prove gain against three drugs One of the three drugs protocol studied as induction was CTD scheme (cyclophosphamide+ thalidomide+dexamethasone). Daratumumab has a novel mechanism of action that results in enhanced activity in combination with existing standards of care, including first-generation novel agents, such as thalidomide, as well as other therapeutics. Considerable responses have been observed in a cohort of heavily pretreated patients with relapsed/refractory MM. The use of a treatment combination with monoclonal antibody associated with immunomodulator (in a four drug combo) can lead to a improvement in response rates and in survival, reflects on a better free time interval. This trial will represent a new option of treatment with a combination of anti CD38 monoclonal antibody (DARATUMUMAB) as induction regimen with CTD protocol (four drug combination). And It use as consolidation and maintenance to give better immunomodulatory response and extended survival and disease control.

NCT ID: NCT03428373 Active, not recruiting - Clinical trials for Multiple Myeloma in Relapse

Rivaroxaban or Aspirin As Thromboprophylaxis in Multiple Myeloma

RithMM
Start date: January 17, 2019
Phase: Phase 2/Phase 3
Study type: Interventional

The intended study is designed as a a phase IV pragmatic multicenter randomized controlled clinical trial, comparing the impact of two different therapies including ASA vs. Rivaroxaban in newly diagnosed or relapsed and refractory multiple myeloma patients treated with Lenalidomide Dexamethasone (Len-Dex) combination therapy. The pilot feasibility study was conducted in preparation for this randomized controlled trial designed to assess the effect of an intervention.

NCT ID: NCT00171925 Terminated - Clinical trials for Multiple Myeloma Stage I

Therapy With Zoledronic Acid in Patients With Multiple Myeloma Stage I

Start date: August 2000
Phase: Phase 3
Study type: Interventional

Multiple myeloma is a disease of B-lymphocytes producing malignant plasma cells. Malignant plasma cells induce osteolytic lesions, which is characteristic for progression of multiple myeloma. It is the aim of this study to investigate whether zoledronic acid has an influence on the progression of multiple myeloma.